HOME >> MEDICINE >> NEWS
New bird flu drug promises to beat the problem of resistance

A new kind of drug to fight bird flu that will not suffer from the same kind of resistance problems as current treatments should begin clinical trials within the next three years, thanks to a new research grant.

Dr Andrew Watts from the University of Bath (UK) and Dr Jennifer McKimm-Breschkin from CSIRO (Australia) have been awarded over 408,000 from the Medical Research Council (MRC) to develop a new class of inhibitor they have discovered into a new kind of antiviral influenza drug.

The search for an alternative flu drug has become all the more pressing as the full extent of resistance the ability of the influenza virus to withstand drug treatments - becomes more widely understood.

Both Tamiflu and Relenza, the two drugs currently being stockpiled by governments in preparation for a global outbreak of bird flu, are inherently susceptible to resistance because of the way they work.

The first major warning of the practical implications of this came with research published in the New England Journal of Medicine in December 2005.

This reported that from a group of eight Vietnamese bird flu patients treated with Tamiflu (also known as Oseltamivir), two patients showed initial signs of recovery before eventually dying. This suggests that the influenza virus was able to rapidly develop resistance to the drug.

In another study in Japan, the virus developed resistance in one in six children treated with Tamiflu for ordinary forms of flu.

Although acting upon the same target on the influenza virus as existing treatments, the new drug molecules being developed are specific for a part of the virus that is unable to mutate (change), which means it should be impossible for the influenza virus to develop resistance.

"Tamiflu and Relenza remain our best lines of defence against a flu pandemic, but we need to be working on better alternatives that do not suffer the same inherent resistance proble
'"/>

Contact: Andrew McLaughlin
a.mclaughlin@bath.ac.uk
44-012-253-86883
University of Bath
7-Aug-2006


Page: 1 2 3

Related medicine news :

1. Fiber-based light source promises improvements in food inspection
2. Eastern philosophy promises hope for Western women with eating disorders
3. BC catalyst discovery promises faster, cheaper drug production
4. Solution to bacterial mystery promises new drugs
5. Purdue chemical-analysis method promises fast results
6. New rheumatoid arthritis drug developed at UCSD promises improved treatment options
7. Biotechnology has failed to live up to its promises
8. Promises made, promises kept?
9. Drug for cluster headaches may cause heart problems
10. Researchers find vitamin B1 deficiency key to vascular problems for diabetic patients
11. High blood pressure problems largely misunderstood by sufferers

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New bird flu drug promises beat the problem resistance

(Date:1/22/2015)... January 23, 2015 LunaDress, with its top ... fashion industry. Now, the business is showing its latest designs ... dresses. , According to the company’s CEO, all the fresh ... offered with big discounts, up to 80% off. All the ...
(Date:1/22/2015)... January 22, 2015 Padre Murphy's and Owner ... of Pro Player Health Alliance (PPHA). The PPHA's ... in getting everyone, including NFL greats, treated for obstructive sleep ... leading groups supporting the cause in the valley. The most ...
(Date:1/22/2015)... January 22, 2015 Blue Cross and Blue ... who exemplify what it means to “Live Fearless.” ... people to share their stories about how they or someone ... inspired others by living in the moment. By telling these ...
(Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post ... insurance . , Purchasing an accidental death and dismemberment ... This type of rider provides benefits if the insured dies ... a lesser form of life insurance. , AD&D is ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
(Date:1/23/2015)... , Jan. 23, 2015  Immune Therapeutics, Inc. today announced the ... the compounding, packaging and distributing of its naltrexone tablets.  The ... United States . KRS Global is ... tablets in various strengths for individual patients in response to ...
(Date:1/23/2015)... 23, 2015  HyGreen, Inc., a leader in hand hygiene ... RCA Medical, a subsidiary of Ascendis Health Limited, in ... Each year, hundreds of millions of patients around the ... are transmitted from patient to patient via the unwashed ...
(Date:1/23/2015)... 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that ... of Lixte,s lead compound, LB‑100, is being conducted, has been ... S. Kovach , M.D., the founder and President of Lixte, ... at a single site. Accrual of patients, however, was slower ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
Cached News: